CN118715204A - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
CN118715204A
CN118715204A CN202280091813.9A CN202280091813A CN118715204A CN 118715204 A CN118715204 A CN 118715204A CN 202280091813 A CN202280091813 A CN 202280091813A CN 118715204 A CN118715204 A CN 118715204A
Authority
CN
China
Prior art keywords
heterocycloalkyl
cycloalkyl
alkyl
group
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280091813.9A
Other languages
English (en)
Chinese (zh)
Inventor
塞缪尔·巴尼斯特
威廉·约尔根森
谭金龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pusilo Private Ltd
Original Assignee
Pusilo Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021904274A external-priority patent/AU2021904274A0/en
Application filed by Pusilo Private Ltd filed Critical Pusilo Private Ltd
Publication of CN118715204A publication Critical patent/CN118715204A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202280091813.9A 2021-12-24 2022-12-23 化合物 Pending CN118715204A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021904274 2021-12-24
AU2021904274A AU2021904274A0 (en) 2021-12-24 Compounds
PCT/AU2022/051592 WO2023115166A1 (en) 2021-12-24 2022-12-23 Compounds

Publications (1)

Publication Number Publication Date
CN118715204A true CN118715204A (zh) 2024-09-27

Family

ID=86900852

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202280091813.9A Pending CN118715204A (zh) 2021-12-24 2022-12-23 化合物
CN202280091811.XA Pending CN118696029A (zh) 2021-12-24 2022-12-23 化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280091811.XA Pending CN118696029A (zh) 2021-12-24 2022-12-23 化合物

Country Status (6)

Country Link
US (2) US20250074873A1 (enExample)
EP (2) EP4452937A4 (enExample)
JP (2) JP2025501630A (enExample)
CN (2) CN118715204A (enExample)
CA (2) CA3244229A1 (enExample)
WO (2) WO2023115167A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
WO2022221415A2 (en) 2021-04-13 2022-10-20 The Regents Of The University Of California Tetracyclic compounds for treating brain disorders
EP4396162A4 (en) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc ASYMMETRIC ALLYL TRYPTAMINES
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス，インク． フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
CA3253725A1 (en) * 2022-05-20 2023-11-23 Caamtech, Inc. TRYPTAMINE DERIVATIVES
AU2023323907A1 (en) * 2022-08-11 2025-02-20 Gilgamesh Pharmaceuticals, Inc. Tryptamines and methods of treating mood disorders
CA3265884A1 (en) * 2022-08-31 2024-03-07 Cybin Irl Limited TRYPTAMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
CN121866243A (zh) * 2023-09-07 2026-04-14 耶路撒冷希伯来大学伊森姆研究发展有限公司 致幻化合物、其制备方法及其用途
WO2025137581A1 (en) * 2023-12-21 2025-06-26 Atai Therapeutics, Inc. Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions
US12679847B1 (en) 2025-08-04 2026-07-14 Nalu Bio, Inc. Aryl-substituted n-alkyl indoles and their use as pharmacologically active agents

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1928892A (en) * 1991-06-21 1993-01-25 Smithkline Beecham Plc Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists
GB9718833D0 (en) * 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
AU767009B2 (en) * 1998-12-11 2003-10-30 Virginia Commonwealth University Selective 5-HT6 receptor ligands
SI1379239T1 (sl) * 2001-03-29 2008-02-29 Lilly Co Eli N-(2-ariletil)benzilamini, uporabljeni kot antagonisti receptorja 5-ht6
KR20050010512A (ko) * 2002-06-12 2005-01-27 스미또모 세이야꾸 가부시키가이샤 인돌, 인다졸 및 벤즈아졸류
CA2508290C (en) * 2002-12-20 2017-02-28 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
ES2564804T3 (es) * 2004-02-12 2016-03-29 Mitsubishi Tanabe Pharma Corporation Compuesto de indazol y uso farmacéutico del mismo
WO2006047032A2 (en) * 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
WO2007046112A1 (en) * 2005-10-19 2007-04-26 Suven Life Sciences Inc. Arylthioether tryptamine derivatives as functional 5-ht6 ligands
WO2008046155A1 (en) * 2006-10-20 2008-04-24 Dia-B Tech Limited Methods for regulating glucose homeostasis and agents therefor
US20090318527A1 (en) * 2008-02-11 2009-12-24 Howard Sard Indole compounds and methods of use thereof
BRPI0916395A2 (pt) * 2008-07-30 2016-02-16 Ferrer Int compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
US8349898B2 (en) * 2008-11-18 2013-01-08 Wisconsin Alumni Research Foundation Sigma-1 receptor ligands and methods of use
US8912220B2 (en) * 2009-08-10 2014-12-16 Galenea Pharmaceuticals Compounds and methods of use thereof
CN103601683B (zh) * 2010-04-16 2016-03-30 中国科学院上海药物研究所 苯并杂环类化合物及其制备方法和用途
USRE47009E1 (en) * 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
LT4084791T (lt) * 2020-02-18 2025-02-25 Gilgamesh Pharmaceuticals, Inc. Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
WO2021179091A1 (en) * 2020-03-12 2021-09-16 Bright Minds Biosciences Inc. 3-(2-(aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-ht2 receptor modulators
IL312785B2 (en) * 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US20230014907A1 (en) * 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
WO2022246554A1 (en) * 2021-05-26 2022-12-01 Bright Minds Biosciences Inc. Heterocyclic compounds and methods of preparation thereof

Also Published As

Publication number Publication date
EP4452937A4 (en) 2025-12-03
WO2023115167A1 (en) 2023-06-29
WO2023115166A1 (en) 2023-06-29
US20250074873A1 (en) 2025-03-06
EP4452938A4 (en) 2025-12-03
CN118696029A (zh) 2024-09-24
JP2025501630A (ja) 2025-01-22
JP2025501629A (ja) 2025-01-22
CA3244229A1 (en) 2023-06-29
US20250101038A1 (en) 2025-03-27
CA3244224A1 (en) 2023-06-29
EP4452937A1 (en) 2024-10-30
EP4452938A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
US20250101038A1 (en) Compounds
CN118974044A (zh) 化合物
JP2025071254A (ja) 気分障害の処置での使用に特異的なトリプタミン
JP2023540329A (ja) アゼチジニルトリプタミン及び精神障害を処置する方法
US12415804B2 (en) Compounds for activating a serotonin receptor
JP7405756B2 (ja) ピロリジンアミド誘導体及びその使用
CN119384406A (zh) 化合物
CN121969606A (zh) 化合物
WO2025118034A1 (en) Compounds active at the serotonergic 5-ht2a receptor
FR2912747A1 (fr) Derives des 1-(1-hydoxy-3-oxo-propen-1-yl)-1,2,3,3a,8,8a-hexahydro- pyrrolo[2,3-b)indoles et leur utilisation en therapeutique

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination